Literature DB >> 15809761

Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer.

Anthony W H Chan1, Michael W Y Chan, Tin-Lap Lee, Enders K W Ng, Wai-Keung Leung, James Y W Lau, Joanna H M Tong, Francis K L Chan, Ka-Fai To.   

Abstract

Death-associated protein kinase (DAP-kinase) is a serine/threonine kinase and a positive mediator of apoptosis. Down-regulation of DAP-kinase was associated with increased metastatic potential of tumors. Gene promoter hypermethylation could lead to down-regulation of DAP-kinase. We aimed to investigate the frequency of gene promoter methylation of DAP-kinase in gastric carcinoma (GCA) and assessed its association with clinicopathological features. One hundred and seven cases of gastric carcinoma were examined. The relevant clinical and pathological features, including survival data were reviewed. Methylation status was assessed by methylation-specific PCR (MSP). Seventy-four cases (69.2%) of GCA demonstrated promoter methylation of DAP-kinase. Methylation of DAP-kinase was observed in intestinal, diffuse and mixed type of GCA. It also occurred in similar frequency among antral, body and cardiac gastric cancer. No association between methylation status and age or gender was demonstrated. However, the methylated cases correlated with the presence of nodal metastasis (p=0.041), advance stage of disease (p=0.029) and a poorer event-free survival (log-rank test p=0.0141). DAP-kinase promoter methylation as a potential prognostic marker for gastric cancer patients deserved further evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809761

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes.

Authors:  Liguo Zhang; Kenneth P Nephew; Patricia J Gallagher
Journal:  J Biol Chem       Date:  2007-02-26       Impact factor: 5.157

Review 2.  Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers.

Authors:  Hasan Raza Kazmi; Soni Kumari; Satendra Tiwari; A Khanna; Gopeshwar Narayan
Journal:  Pathol Oncol Res       Date:  2018-03-19       Impact factor: 3.201

Review 3.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

4.  Epigenetic contributions to cancer metastasis.

Authors:  David I Rodenhiser
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

Review 5.  New blood markers detection technology: A leap in the diagnosis of gastric cancer.

Authors:  Maneesh K Beeharry; Wen-Tao Liu; Min Yan; Zheng-Gang Zhu
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer.

Authors:  Wei Kang; Joanna H M Tong; Anthony W H Chan; Raymond W M Lung; Shuk Ling Chau; Queenie W L Wong; Nathalie Wong; Jun Yu; Alfred S L Cheng; Ka Fai To
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

7.  Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.

Authors:  F Christoph; C Kempkensteffen; S Weikert; J Köllermann; H Krause; K Miller; M Schostak; M Schrader
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

Review 8.  Epigenetic alterations in gastric cancer (Review).

Authors:  Du-Guan Fu
Journal:  Mol Med Rep       Date:  2015-05-22       Impact factor: 2.952

Review 9.  Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.

Authors:  Wenzhuo Jia; Tao Yu; Xianglong Cao; Qi An; Hua Yang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 10.  Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: A systematic review and meta-analysis.

Authors:  Wenzheng Yuan; Jinhuang Chen; Yan Shu; Sanguang Liu; Liang Wu; Jintong Ji; Zhengyi Liu; Qiang Tang; Zili Zhou; Yifeng Cheng; Bin Jiang; Xiaogang Shu
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.